OncoKB New Data Release - August 26, 2025
Contact OncoKB
Data Release v5.1
August 26, 2025
What's New
Update to our FDA-Approved Oncology Therapies page
Updated Therapeutic Implications:
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 1: Addition of Zongertinib to ERBB2 Tyrosine kinase activating domain mutations in non-small cell lung cancer based on FDA approval of zongertinib for non-squamous non-small cell lung cancer with HER2 tyrosine kinase domain activating mutations (PMID: 40293180)
Tyrosine kinase domain activating mutations include: V697L, Q709L, A710V, E717D, L726F, L726I, T733I, L768S, L755A, L755P, L755S, L755W, I767M, D769H, D769Y, V773L, G776S, G776V, V777L, V777M, V794M, T798M, D808N, G815R, D821N, L841V, V842I, L866M, L869R, 770_831ins
Level 1 sensitivity-associated therapeutics currently in OncoKB™ for ERBB2 Tyrosine kinase domain activating mutations in non-small cell lung cancer: Trastuzumab Deruxtecan
Gene Curation:
Addition of 4 new genes:
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
